Therapy outcomes of IL-17 and JAK inhibitors in rosacea:A systematic review
Xinyi Dai
Chenxingyue Zhang
Zhiqiang Yin
Abstract：Dear Editor,
Rosacea is characterized by persistent or transient erythema, papules, pustules, telangiectasia, and/or phymatous lesions[1]. Although multiple treatments are available for rosacea, the advent of biological agents and small-molecule agents has significantly advanced our ability to target the disease more effectively[2]. In the current review, we summarize the outcomes of targeted therapies in rosacea, mainly focusing on interleukin (IL)-17 inhibitors and Janus kinase (JAK) inhibitors.
Machine-generated Keywords：
Publication Date：2025-05-30
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：2( 317-318 )